INCY: Other (8-K)
· The NYC Memo
Incyte is halting plans for the Phase 3 MAESTRA-3 study of CDK2 inhibitor INCB123667 due to portfolio prioritization. While stated not to affect financial guidance, Phase 3 pipeline discontinuations represent notable clinical developments for biotech investors.